Co-op, Advanced Cell Engineering
Strand Therapeutics
Summary
Strand is looking for people who have the enthusiasm and motivation to be a highly contributing member of a small but extremely productive team. This opportunity will offer the employee the ability to work in a matrix-based environment and be a part of the future strategy of the company.
Job description
Job Summary
Strand is looking for people who have the enthusiasm and motivation to be a highly contributing member of a small but extremely productive team. This opportunity will offer the employee the ability to work in a matrix-based environment and be a part of the future strategy of the company.
We are looking for a highly motivated and innovative candidate for the role of Co-op, Advanced Cell Engineering. This is a fantastic opportunity to make a significant impact as a scientifically motivated self-starter capable of independently conceiving, conducting, and critically analyzing their own work with minimal supervision.
Primary Responsibilities
- Generate, expand, and maintain stable mammalian cell lines expressing proteins of interest.
- Develop and optimize flow cytometry assays to characterize cell lines, including protein expression levels and stability over time.
- Perform mammalian cell transfections and downstream functional assays such as in vitro cytotoxicity and ELISA assays.
- Execute experiments, maintain accurate laboratory records, and contribute to troubleshooting experiments with the team.
- Working across diverse areas to support the group's research activities in a fast-paced and collaborative environment.
Qualifications
- On track to graduate with a BS or MS in Biology, Biochemistry, Bioengineering, or a related discipline.
- 1-3 years of research experience in a biotechnology, pharmaceutical, and/or academic environment is preferred.
- Experience with mammalian cell culture, transfection, and flow cytometry is preferred.
- Hands on experience with ELISAs, viral transductions, and RNA handling is a plus.
- Exposure to immune cell assays such as immune cells isolation, phenotyping, and co-culture is a great bonus.
- Ability to write, edit, and follow standard operating procedures, make careful observations, and maintain clear and complete records of lab work.
Requirements
- On track to graduate with a BS or MS in Biology, Biochemistry, Bioengineering, or a related discipline
- 1-3 years of research experience in a biotechnology, pharmaceutical, and/or academic environment is preferred
- Experience with mammalian cell culture, transfection, and flow cytometry is preferred
- Hands on experience with ELISAs, viral transductions, and RNA handling is a plus
- Exposure to immune cell assays such as immune cells isolation, phenotyping, and co-culture is a great bonus
- Ability to write, edit, and follow standard operating procedures, make careful observations, and maintain clear and complete records of lab work
Company overview
Strand Therapeutics is a pioneering biotechnology company founded in 2017 by researchers from MIT's Synthetic Biology Center. The company is developing the world's first platform for creating programmable, long-acting mRNA therapeutics capable of delivering precise, multi-functional, and potentially curative treatments. Strand's innovative approach involves embedding mRNA therapeutics with sophisticated genetic logic circuits that enable them to identify specific cell types and activate only in diseased cells, while remaining inactive in healthy tissues. This technology dramatically increases the therapeutic window and safety profile of mRNA medicines. The company's proprietary mRNA programming language allows for precise control over the location, timing, intensity, and duration of protein expression, representing a significant advancement in synthetic biology applications for medicine. Strand is currently advancing a pipeline of programmable mRNA therapeutics focused on cancer and other life-threatening diseases, with their lead candidate STX-001 already in Phase 1 clinical trials for solid tumors. The company has raised over $256 million in funding from prominent investors including Kinnevik, Regeneron, Eli Lilly, and Amgen.